Stratwell Services image

Our B2B Products

Our B2B Products

Our B2B Products

Our products

ViaDerma's product pipeline is built on the clinical strength of the patented SkinPass™ technology

SkinPass™ technology fuels our entire family of topical solutions. Because this delivery platform is both patented and versatile, we have engineered a vast portfolio of specialized medicines designed to bypass the epidermal barrier and deliver institutional-grade healing directly to the source of infection or inflammation.

Shop

Buy VitaStem

Direct Home Delivery
Get the clinical power of SkinPass™ technology delivered straight to your door.

Easy At-Home Application
Simply apply the drops directly to the affected area.

Rapid Recovery
Experience professional-grade healing for cuts and burns by formula that kills 99.9% bacteria.

Buy Now

Shop

Buy VitaStem

Direct Home Delivery
Get the clinical power of SkinPass™ technology delivered straight to your door.

Easy At-Home Application
Simply apply the drops directly to the affected area.

Rapid Recovery
Experience professional-grade healing for cuts and burns by formula that kills 99.9% bacteria.

Buy Now

ViaDerma Pilot
ViaDerma Pilot

Instructions for Use

Four-Step Instruction.

Four-Step Instruction.
Three times daily.

01

Apply directly

Apply as droplets directly to the wound bed. Use enough to cover the affected tissue.

02

Massage in lightly

With clean, gloved hands, lightly massage the solution into the tissue.

03

Cover if needed

Cover with dressing for protected sites. Leave open for hot spots and superficial lesions.

04

Three times daily

Repeat application three times daily until full healing.

Powered by SkinPass™

Patented Faster Absorption
and Penetration

Deeper, faster delivery for topical medications — throughout the entire lesion.

Explore the technology

01 Penetrates Skin Barrier

02 Targets Entire Infection

03 Creates Protective Barrier

Intellectual Property

A Protected Global Patent

Our technology is anchored by a robust and expanding intellectual property portfolio.

U.S. Patent No. 12,465,567: Awarded in 2025, this covers our "Enhanced Antibiotic and Drug Delivery" for both human and veterinary applications.

Strategic Exclusivity: Our portfolio includes 20 additional Continuation-in-Part (CIP) patent applications, establishing Via Pellé’s dominance in the transdermal delivery landscape.

Our technology is anchored by a robust and expanding intellectual property portfolio.

U.S. Patent No. 12,465,567: Awarded in 2025, this covers our "Enhanced Antibiotic and Drug Delivery" for both human and veterinary applications.

Strategic Exclusivity: Our portfolio includes 20 additional Continuation-in-Part (CIP) patent applications, establishing Via Pellé’s dominance in the transdermal delivery landscape.

CTA Image

Learn more on a call with a specialist

Schedule a free consultation with our sales team representative and discover how Via Pellé can bring innovation into your medical facility

Contact Us

CTA Image

Learn more on a call with a specialist

Schedule a free consultation with our sales team representative and discover how Via Pellé can bring innovation into your medical facility

Contact Us

CTA Image

Learn more on a call with a specialist

Schedule a free consultation with our sales team representative and discover how Via Pellé can bring innovation into your medical facility

Contact Us